Goff, Laura Williams

Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy

Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 41

Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.

Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y. S., Sahin, I. H., Shyr, Y., Chu, S.-K., Lin, E. P.-Y., Hsu, C.-Y., Goff, L. W., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 15

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

Ma, W. W., Zhu, M., Lam, E. T., Diamond, J. R., Dy, G. K., Fisher, G. A., Goff, L. W., Alberts, S., Bui, L. A., Sanghal, A., et al. (2021) · Cancer Chemotherapy and Pharmacology

Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery

Cited by 12